Abstracts Archive - Page 1476 of 2425 - ACR Meeting Abstracts

Abstract Number: 874 • 2016 ACR/ARHP Annual Meeting
Expression and Function of IL-12/23 Related Cytokine Subunits (p35, p40 and p19) in Giant-Cell Arteritis Lesions. Potential Role of p40 in Promoting Th1 -Mediated Pathways
Georgina Espígol-Frigolé¹, Ester Planas-Rigol¹, Ester Lozano², Marc Corbera-Bellalta², Nekane Terrades-Garcia², Sergio Prieto-González¹, Ana García-Martínez³, Jose Hernández-Rodríguez² and Maria C. Cid⁴, ¹Department of Autoimmune and Systemic Diseases, Hospital Clínic. University of Barcelona. IDIBAPS, Barcelona, Spain, ²Vasculitis Research Unit. Department of Autoimmune Diseases, Hospital Clínic. University of Barcelona. IDIBAPS, Barcelona, Spain, ³Emergeny Department, Hospital Clínic. University of Barcelona. IDIBAPS, Barcelona, Spain, ⁴Autoimmune and Systemic Diseases, Hospital Clínic. University of Barcelona. IDIBAPS, Barcelona, Spain
Background/Purpose: GCA has been considered a Th1-mediated disease. In recent years it has become apparent that Th17-mediated mechanisms may also play a role in GCA…
Abstract Number: 875 • 2016 ACR/ARHP Annual Meeting
Pericardial Involvement in Biopsy-Proven Giant-Cell Arteritis (GCA) Patients Detected By CT Angiography (CTA): Prevalence at Diagnosis and Outcome with Glucocorticoid (GC) Treatment
Javier Marco-Hernández¹, Sergio Prieto-González², Rosa Gilabert³, Pedro Arguis⁴, Georgina Espígol-Frigolé⁵, Ana García-Martínez⁶, Ester Planas-Rigol⁵, Marc Corbera-Bellalta², Nekane Terrades-Garcia², Jose Hernández-Rodríguez² and Maria C. Cid⁷, ¹Internal Medicine, Hospital Clínic, Barcelona, Spain, ²Vasculitis Research Unit. Department of Autoimmune Diseases, Hospital Clínic. University of Barcelona. IDIBAPS, Barcelona, Spain, ³Center for Diagnostic Imaging, Hospital Clínic, Barcelona, Spain, ⁴Center for Diagnostic Imaging, Hospital Clínic. IDIBAPS. University of Barcelona, Barcelona, Spain, ⁵Department of Autoimmune and Systemic Diseases, Hospital Clínic. University of Barcelona. IDIBAPS, Barcelona, Spain, ⁶Emergeny Department, Hospital Clínic. University of Barcelona. IDIBAPS, Barcelona, Spain, ⁷Autoimmune and Systemic Diseases, Hospital Clínic. University of Barcelona. IDIBAPS, Barcelona, Spain
Background/Purpose: In GCA, cranial artery involvement is particularly frequent and underlies the classical manifestations and complications of the disease. Symptomatic pericarditis has been occasionally described…
Abstract Number: 876 • 2016 ACR/ARHP Annual Meeting
Long Term Efficacy of Ustekinumab for the Treatment of Giant Cell Arteritis
Richard Conway¹, Lorraine O'Neill², Phil Gallagher³, Eileen O'Flynn⁴, Geraldine M. McCarthy⁵, Conor Murphy⁶, Douglas J. Veale⁷, Ursula Fearon⁸ and Eamonn S. Molloy⁹, ¹CARD Newman Research Fellow, University College Dublin, Dublin, Ireland, ²Rheumatology, St. Vincent's University Hospital, Dublin, Ireland, ³St. Vincent's University Hospital, Department of Rheumatology, Dublin, Ireland, ⁴Rheumatology, Dublin Academic Medical Centre, St. Vincent's University Hospital, Dublin, Ireland, ⁵Div of Rheumatology, Mater Misericordiae University Hospital, Dublin, Ireland, ⁶Department of Ophthalmology, Royal Victoria Eye and Ear Hospital, Dublin, Ireland, ⁷Centre for Arthritis and Rheumatic Diseases, Dublin Academic Medical Centre, University College Dublin, Dublin 4, Ireland, ⁸Trinity College Dublin, Department of Molecular Rheumatology, Trinity College Dublin, Dublin, Ireland, ⁹Rheumatology, Centre for Arthritis and Rheumatic Diseases, Dublin Academic Medical Centre, St Vincent's University Hospital, Dublin, Ireland
Background/Purpose: Giant cell arteritis (GCA) requires treatment with high dose corticosteroids with attendant significant adverse events. There is a critical need for alternative therapies. Interleukins…
Abstract Number: 877 • 2016 ACR/ARHP Annual Meeting
Risk of Coronary Artery Disease in Patients with Polymyalgia Rheumatica: A Systematic Review and Meta-Analysis
Patompong Ungprasert¹, Matthew J. Koster², Kenneth J. Warrington³ and Eric L. Matteson¹, ¹Rheumatology, Mayo Clinic, Rochester, MN, ²Rheumatology, University of California Los Angeles, CA, USA Mayo Clinic, Rochester, MN, ³Rheumatology, University of California Los Angeles, CA, USA Mayo, Rochester, MN
Risk of Coronary Artery Disease in Patients with Polymyalgia Rheumatica: A Systematic Review and Meta-analysis Background/Purpose: Several chronic inflammatory disorders, such as rheumatoid arthritis and…
Abstract Number: 878 • 2016 ACR/ARHP Annual Meeting
Giant-Cell Arteritis Related Stroke: A Retrospective Multicentre Case-Control Study
Hubert de Boysson¹, Eric Liozon², Delphine Lariviere³, Maxime Samson⁴, Jonathan Boutemy¹, Gwénola Maigné¹, Nicolas Martin Silva¹, Achille Aouba¹, Karim Sacre³ and Boris Bienvenu⁵, ¹Department of Internal Medicine, Caen University Hospital, Caen, France, ²Departement of Internal Medicine, Limoges University Hospital, Limoges, France, ³Department of Internal Medicine, Bichat Hospital, Paris, France, ⁴Dijon University Hospital, Dijon, France, ⁵Caen University Hospital, Caen, France
Background/Purpose: Our aim was to describe patients with Giant-Cell Arteritis (GCA)-related stroke and to compare them to a control group of GCA patients without cerebrovascular involvement.…
Abstract Number: 879 • 2016 ACR/ARHP Annual Meeting
Associated Inflammatory Diseases in Takayasu’s Arteritis: The Many Faces of a Disease
Sinem Nihal Esatoglu¹, Ayse Merve Celik², Didar Ucar³, Aykut Ferhat Celik⁴, Serdal Ugurlu⁵, Gulen Hatemi⁵, Melike Melikoglu⁵, Izzet Fresko⁵, Vedat Hamuryudan⁵, Huri Ozdogan⁶, Sebahattin Yurdakul⁵, Hasan Yazici⁵ and Emire Seyahi⁵, ¹Rheumatology, Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ²Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Istanbul, Turkey, ³Istanbul University, Cerrahpasa Medical Faculty, Department of Ophthalmology, Istanbul, Turkey, ⁴Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Gastroenterology, Istanbul, Turkey, ⁵Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ⁶Division of Rheumatology, Department of Internal Medicine, Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey
Background/Purpose: Case reports and series suggest that Takayasu’s arteritis (TA) can co-exist with various inflammatory disorders. Inflammatory bowel disease [(IBD; Crohn's disease (CD) or ulcerative…
Abstract Number: 880 • 2016 ACR/ARHP Annual Meeting
Pilot Study of Microbubble Contrast-Enhanced Vascular Ultrasonography: A Novel Method of Detecting Large Vessel Vasculitis?
Kimberly P. Liang¹, Douglas P. Landsittel², Bernadette B. Sendon³, Donald M. Jones⁴, Suresh R. Mulukutla⁵, Steven E. Reis⁶, Ali Hakim Shoushtari⁷ and Larry W. Moreland⁸, ¹Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ²Medicine, University of Pittsburgh, Pittsburgh, PA, ³Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁴Rheumatology & Clinical Immunology, Univ of Pittsburgh Med Ctr, Pittsburgh, PA, ⁵Division of Cardiology, University of Pittsburgh, Pittsburgh, PA, ⁶Division of Cardiology and Department of Clinical and Translational Science, University of Pittsburgh, Pittsburgh, PA, ⁷Clinical and Translational Science Institute, University of Pittsburgh, Pittsburgh, PA, ⁸Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: A key unmet need in the monitoring of disease activity in large vessel vasculitides (LVV), i.e., giant cell arteritis (GCA) and Takayasu arteritis…
Abstract Number: 881 • 2016 ACR/ARHP Annual Meeting
Cardiopulmonary Involvement in Takayasu Arteritis
David Brennan¹, Kenneth J. Warrington², Jean Schmidt³, Cynthia S. Crowson⁴ and Matthew J. Koster⁵, ¹Internal Medicine, Mayo Clinic, Rochester, MN, ²Rheumatology, Mayo Clinic, Rochester, MN, ³Department of Internal Medicine and RECIF, Amiens University Hospital, Amiens, France, ⁴Health Sciences Research, Mayo Clinic, Rochester, MN, ⁵Rheumatology, University of California Los Angeles, CA, USA Mayo Clinic, Rochester, MN
Background/Purpose: Takayasu arteritis (TAK) is an inflammatory large-vessel vasculitis of unknown etiology affecting the proximal aorta and its primary branches. Heart disease is a major…
Abstract Number: 882 • 2016 ACR/ARHP Annual Meeting
Polymyalgia Rheumatica Activity Score without C-Reactive Protein
Valerie Devauchelle^1,2, Lea Saraux³, Jean-Marie Berthelot⁴, Divi Cornec⁵, Thierry Marhadour⁶, Sandrine Jousse-Joulin⁷, Michel De Bandt⁸, Maelenn Gouillou⁹ and Alain Saraux¹⁰, ¹Rheumatology, Brest university medical school, EA 2216, Lab Ex, INSERM, IGO,UBO and CHU de la Cavale Blanche,, Brest, France, ²Service de Rhumatologie, Department of Rheumatology, Brest University Hospital, Brest, France, Brest, France, ³Rheumatology, CHU Brest, Brest, France, ⁴Rheumatology Unit, Nantes University Hospital, Nantes, France, ⁵Department of rheumatology, Brest Occidentale University, Brest, France, ⁶Rheumatology, CHU La Cavale Blanche, Brest, France, ⁷Rheumatology, CHu La cavle Blanche, Brest, France, ⁸CHU Fort de France, Fort de France, France, ⁹Clinical Investigation Centre (CIC) 1412, CHU Cavale Blanche- Institut National de la Santé et de la Recherche Médicale (INSERM), Brest, France, ¹⁰Department of rheumatology and unit of immunology (EA 2216), CHU Brest et Université Bretagne Occidentale, Brest, France
Background/Purpose: Disease activity of polymyalgia rheumatica (PMR) (1, 2) may be evaluated using the PMR activity score (PMR-AS). For patients without measure of CRP, or patients…
Abstract Number: 883 • 2016 ACR/ARHP Annual Meeting
Folate Receptor Beta and Endothelin Receptor Beta Macrophage Subtypes Are Differentially Expressed in the Vascular Compartments of the Intima and Media/Adventitia in Giant Cell Arteritis: A Pilot Study
Shirley Albano-Aluquin¹, Nancy J. Olsen¹ and Jozef Malysz², ¹Medicine/Rheumatology, Penn State Hershey Medical Center, Hershey, PA, ²Pathology, Penn State University College of Medicine, Hershey, PA
Background/Purpose: Giant cell arteritis (GCA) is a chronic immune-mediated vasculitis of large and medium vessels characterized by a chronic relapsing course with no good biomarkers…
Abstract Number: 884 • 2016 ACR/ARHP Annual Meeting
Health-Related Quality of Life in Giant Cell Arteritis
Tanaz A. Kermani¹, Antoine Sreih², Gunnar Tomasson³, David Cuthbertson⁴, Simon Carette⁵, Gary S. Hoffman⁶, Nader A. Khalidi⁷, Curry L. Koening⁸, Carol A. Langford⁹, Carol A. McAlear¹⁰, Paul A. Monach¹¹, Larry W. Moreland¹², Christian Pagnoux¹³, Philip Seo¹⁴, Kenneth J. Warrington¹⁵, Steven R. Ytterberg¹⁶ and Peter A. Merkel¹⁷, ¹Rheumatology, University of California Los Angeles, Santa Monica, CA, ²Department of Rheumatology, University of Pennsylvania, Philadelphia, PA, ³Dept of Public Health Sciences, University of Iceland, Reykjavik, IS, ⁴Biostatistics and Informatics, Department of Pediatrics, University of South Florida, Tampa, FL, ⁵Division of Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁶Rheumatic & Immunologic Dis, Cleveland Clinic Foundation, Cleveland, OH, ⁷McMaster University, St Joseph's Healthcare Hamilton, Hamilton, ON, Canada, ⁸Rheumatology, University of Utah, Salt Lake City, UT, ⁹Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, ¹⁰University of Pennsylvania, Philadelphia, PA, ¹¹Rheumatology, Boston University School of Medicine, Boston, MA, ¹²Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ¹³Division of Rheumatology, Mount Sinai Hospital, University Health Network, University of Toronto, Toronto, Canada, Toronto, ON, Canada, ¹⁴Division of Rheumatology, Johns Hopkins University, Baltimore, MD, ¹⁵Rheumatology, University of California Los Angeles, CA, USA Mayo, Rochester, MN, ¹⁶Rheumatology, Mayo Clinic, Rochester, MN, ¹⁷Division of Rheumatology, University of Pennsylvania, Philadelphia, PA
Background/Purpose: To evaluate health-related quality of life (HRQoL) in a large cohort of patients with giant cell arteritis (GCA) as measured by the 36-item…
Abstract Number: 885 • 2016 ACR/ARHP Annual Meeting
Giant Cell Arteritis and Malignancy – More Than Just a Coincidence?
Rok Jese¹, Alojzija Hocevar¹, Ziga Rotar¹, Sonja Praprotnik² and Matija Tomsic¹, ¹Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia, ²Department of Rheumatology, University Medical Centre Ljubljana, Slovenia, Ljubljana, Slovenia
Background/Purpose: Malignancy associated vasculitis represents 2–5% of systemic vasculitides. While there have been reports of increased incidence of malignancy in patients with giant cell arteritis…
Abstract Number: 886 • 2016 ACR/ARHP Annual Meeting
Vascular Inflammation Assessed By 18f-Fludeoxyglucose Positron Emission Tomography (FDG-PET) Is Modified By Treatment in Patients with Large Vessel Vasculitis
Shubhasree Dutta Choudhury¹, Sara Alehashemi², Mark Ahlman³, Ali Cahid Civelek³, Elaine Novakovich⁴, Ashkan Malayeri³, Thomas Cupps⁵, David A. Bluemke⁶ and Peter C. Grayson⁷, ¹National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, MD, ²Rheumatology, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ³Radiology and Imaging Sciences, National Institutes of Health, Bethesda, MD, ⁴Systemic Autoimmunity Branch, NIAMS, National Institutes of Health, Bethesda, MD, ⁵Division of Rheumatology, Immunology and Allergy, Medstar Georgetown University Hospital, Washington DC, DC, ⁶National Institutes of Health, Bethesda, MD, ⁷National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD
Background/Purpose: Methods: Results: Conclusion:
Abstract Number: 887 • 2016 ACR/ARHP Annual Meeting
Fatigue and Physical Functioning in Patients with Giant Cell Arteritis
Gunnar Tomasson¹, John T. Farrar², David Cuthbertson³, Susan Ashdown⁴, Don Gebhart⁵, Georgia Lanier⁶, Nataliya Milman⁷, Jacqueline Peck⁴, Joanna C. Robson^8,9, Judy A. Shea¹⁰, Simon Carette¹¹, Gary S. Hoffman¹², Nader A. Khalidi^13,14, Curry L. Koening¹⁵, Carol A. Langford¹⁶, Carol A McAlear¹⁷, Paul A. Monach¹⁸, Larry W. Moreland¹⁹, Christian Pagnoux²⁰, Antoine G. Sreih²¹, Kenneth J. Warrington²², Steven R. Ytterberg²³ and Peter A. Merkel²⁴, ¹Dept of Public Health Sciences, University of Iceland, Reykjavik, IS, ²University of Pennsylvania, Philadelphia, PA, ³Biostatistics and Informatics, Department of Pediatrics, University of South Florida, Tampa, FL, ⁴Oxford, Oxford, United Kingdom, ⁵Columbus, Columbus, OH, ⁶NONE, Framingham, MA, ⁷University of Ottawa Department of Medicine, University of Ottawa Division of Rheumatology, Ottawa, ON, Canada, ⁸School of Clinical Sciences, University of Bristol, Bristol, United Kingdom, ⁹Faculty of Health and Applied Science, University of the West of England, Bristol, United Kingdom, ¹⁰Division of General Internal Medicine, University of Pennsylvania, Philadelphia, PA, ¹¹Division of Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ¹²Rheumatology, Cleveland Clinic, Cleveland, OH, ¹³Rheumatology, McMaster University, Hamilton, ON, Canada, ¹⁴Division of Rheumatology, McMaster University, Hamilton, ON, Canada, ¹⁵Rheumatology, University of Utah, Salt Lake City, UT, ¹⁶Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, ¹⁷Penn Vasculitis Center, Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ¹⁸Rheumatology, Boston University School of Medicine, Boston, MA, ¹⁹Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ²⁰Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ²¹Rheumatology, The University of Pennsylvania, Philadelphia, PA, ²²Rheumatology, University of California Los Angeles, CA, USA Mayo, Rochester, MN, ²³Rheumatology, Mayo Clinic, Rochester, MN, ²⁴Division of Rheumatology, University of Pennsylvania, Philadelphia, PA
Background/Purpose: Physical function is an established outcome measure for many rheumatic diseases and fatigue is a common disease manifestation across most, if not all,…
Abstract Number: 888 • 2016 ACR/ARHP Annual Meeting
Prevalence of Takayasu Arteritis in Young Women Presenting with Acute Ischemic Heart Disease
Giulio Cavalli, Alessandro Tomelleri, Elena Baldissera and Lorenzo Dagna, Internal Medicine and Clinical Immunology, Vita-Salute San Raffaele University, Milan, Italy
Background/Purpose: Ischemic heart disease (IHD) is classically considered a disease of older men. However, 10% of myocardial infarctions occur in patients aged <45; also, in…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].